AN EXPERIMENTAL STUDY OF PROTECTIVE AND THERAPEUTIC EFFECTS OF PROBIOTICS ON INFECTION BY TOXOPLASMA GONDII | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Article 20, Volume 53, Issue 2, August 2023, Page 369-380 PDF (2.12 MB) | ||||
| DOI: 10.21608/jesp.2023.312183 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| SALWA OSHIBA1; GEHAN SADEK1; DINA ALLAM2; TAHANY AL-ATTAR1 | ||||
| 1Department of Parasitology | ||||
| 2Department of Pathology | ||||
| Abstract | ||||
| One of the most significant opportunistic parasites causing serious infections in humans is Toxoplasma gondii (T. gondii). Lack of maximally effective therapeutic drugs for chronic toxoplasmosis necessitates the search for a reliable and safe toxoplasmosis therapy. This study evaluated, compared, and contrasts the curative and preventative effects of probiotics on mice infected with the ME49 strain of T. gondii, as well as to contrast these effects with those of spiramycin. Probiotic effects were assessed using research in parasitology, histopathology, immunology, and immunohistochemistry. The results showed that probiotics were more helpful when administered as a preventative measure than when provided as a treatment for toxoplasmosis. Toxoplasma gondii cyst counts in the brain were successfully decreased by probiotics. The inflammation in the heart, eyes, and brain also lessened as a result. Besides, it led to a rise in interleukin-10 (IL-10) and a fall in Interferon-gamma (IFN-γ) serum levels. In the brain, heart, and eyes, it also reduced the expression of cluster of differentiation 3 (CD3) and Caspase3. It was less effective than spiramycin, nevertheless, as a therapy | ||||
| Keywords | ||||
| Toxoplasma; Probiotics; Experimental; Prophylaxis; Treatment | ||||
|
Statistics Article View: 74 PDF Download: 119 |
||||
